Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Mainz BioMed NV

< Previous 1 2 3 Next >
Mainz Biomed to Attend 2025 Maxim Growth Summit
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Enters into Technology Partnership with EDX Medical Group
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Expands into Switzerland with labor team w
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
From Mainz BioMed NV
Via GlobeNewswire
Tickers DGX MYNZ
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Stock Split
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ TMO
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.